Revance Therapeutics

$26.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.91 (+3.59%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RVNC and other stocks, options, and ETFs commission-free!

About RVNC

Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN. The listed name for RVNC is Revance Therapeutics, Inc. Common Stock.

CEO
Mark J. Foley
Employees
193
Headquarters
Nashville, Tennessee
Founded
1999
Market Cap
1.86B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
542.71K
High Today
$26.73
Low Today
$24.94
Open Price
$25.56
Volume
721.25K
52 Week High
$34.62
52 Week Low
$11.78

RVNC Earnings

-$1.34
-$1.18
-$1.02
-$0.86
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$1.24 per share
Actual
-$1.24 per share
Replay Earnings Call

You May Also Like

NVSAU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure